The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03480776




Registration number
NCT03480776
Ethics application status
Date submitted
14/03/2018
Date registered
29/03/2018
Date last updated
14/04/2020

Titles & IDs
Public title
ASA in Prevention of Ovarian Cancer (STICs and STONEs)
Scientific title
A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women With BRCA 1/2 Mutations (STICs and STONEs)
Secondary ID [1] 0 0
OV25
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ovarian Cancer Prevention 0 0
Condition category
Condition code
Cancer 0 0 0 0
Ovarian and primary peritoneal

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Acetylsalicylic acid
Other interventions - Placebo

Active Comparator: Acetylsalicylic Acid (ASA) -

Sham Comparator: Placebo -


Treatment: Drugs: Acetylsalicylic acid
81 mg PO daily or 325 mg PO daily

Other interventions: Placebo
One tablet PO daily

Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of pre- & malignant lesions found during prophylactic risk reduction surgery using a stratified Cochran-Mantel-Haenszel test
Timepoint [1] 0 0
5 years
Secondary outcome [1] 0 0
Acceptance of the ASA intervention from the self-report Credibility/Expectancy Questionnaire
Timepoint [1] 0 0
5 years
Secondary outcome [2] 0 0
Compliance of taking ASA by serum monitoring
Timepoint [2] 0 0
5 years

Eligibility
Key inclusion criteria
- Previously documented germline BRCA1/2 pathogenic mutation or likely pathogenic
variant based on the ACMG 2015 guidelines

- Risk-reducing surgery (bilateral salpingo-oophorectomy or bilateral salpingectomy
inclusive of fimbria) scheduled for within 6 months to 2 years after the date of
randomization as standard of care, for women who have completed their families

- ECOG performance status 0 or 1

- Age = 18 years old

- Subject is able (i.e. sufficiently literate) and willing to complete the
Credibility/Expectancy questionnaire in English or French.

- Subject consent must be appropriately obtained in accordance with applicable local and
regulatory requirements. Each subject must sign a consent form prior to enrollment in
the trial to document their willingness to participate

- Subjects must be accessible for treatment and follow up. Subjects randomized on this
trial must be treated and followed at the participating centre.

- In accordance with CCTG policy, protocol treatment is to begin within 2 working days
after subject randomization

- Women of childbearing potential must have agreed to use a highly effective
contraceptive method for the duration of the study treatment and for 30 days post last
dose of study medication
Minimum age
18 Years
Maximum age
No limit
Gender
Females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- Subjects with history of other malignancies, except:

- adequately treated non-melanoma skin cancer;

- curatively treated in-situ cancer of the cervix;

- previously diagnosed (at any point) breast cancer, treated with curative intent;
prior chemotherapy is allowed and the last dose must be = 12 months prior to
randomization; endocrine therapy for breast cancer is allowed at any time.

- other solid tumours curatively treated with no evidence of disease for > 5 years.

- Subjects who have been treated with any PARP-inhibitors (e.g. olaparib) at any time.

- Subjects with active bleeding or bleeding diathesis.

- Subjects with active peptic ulcer.

- Subjects with renal, hepatic or congestive heart failure.

- Subjects with concurrent use of anti-coagulants and/or anti-platelet agents.

- Subjects with prior bilateral salpingectomy.

- Subjects with history of chronic daily use of ASA or NSAIDs.

- Subjects with intolerance of ASA including subjects with a history of asthma induced
by salicylates or substances with a similar action, notably
non-steroidal-anti-inflammatory drugs.

- Ongoing or planned pregnancy.

- Subjects who are breastfeeding.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Prince of Wales Hospital - Randwick
Recruitment hospital [2] 0 0
Westmead Hospital - Westmead
Recruitment hospital [3] 0 0
Peter McCallum Cancer Institute - Melbourne
Recruitment postcode(s) [1] 0 0
2031 - Randwick
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
3002 - Melbourne
Recruitment outside Australia
Country [1] 0 0
Canada
State/province [1] 0 0
Alberta
Country [2] 0 0
Canada
State/province [2] 0 0
British Columbia
Country [3] 0 0
Canada
State/province [3] 0 0
Manitoba
Country [4] 0 0
Canada
State/province [4] 0 0
Newfoundland and Labrador
Country [5] 0 0
Canada
State/province [5] 0 0
Ontario
Country [6] 0 0
Canada
State/province [6] 0 0
Quebec

Funding & Sponsors
Primary sponsor type
Other
Name
Canadian Cancer Trials Group
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Apotex Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
While ASA is not a cancer medication, research suggests that taking ASA reduces the
probability of getting many types of cancer because of its anti-inflammatory action.
Inflammation in the ovaries during ovulation is thought to contribute to the development of
ovarian cancer, and, because ASA is an anti-inflammatory medication, it may help to prevent
it.
Trial website
https://clinicaltrials.gov/show/NCT03480776
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Amit Oza
Address 0 0
Univ. Health Network-OCI/Princess Margaret Hospital, Toronto, ON Canada
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Wendy Parulekar
Address 0 0
Country 0 0
Phone 0 0
613-533-6430
Fax 0 0
Email 0 0
wparulekar@ctg.queensu.ca
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT03480776